Company Overview
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Why Investors Should Care
Revenue has grown at a 29.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $234.60M (+157.0% YoY); net profit $-13.23M.
- Trailing 12 Months Year-on-year growth — revenue -8.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 29.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 29.58% |
| 1 Year: | -8.00% |
Stock Price Performance
| 1 Year: | +311.20% |
| 6 Months: | +53.76% |
| 3 Months: | +12.77% |
| 1 Month: | +3.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 29.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANAB AnaptysBio, Inc. R2KR3KPHARMA | 56.80 | -55.69 | $1.68B | 0.00% | 14.70% | -114.55% | 29.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 5.00M | - | 0 | 5.00M | 0 | - | 15.00M | 0 | 0 | 11.25M | 30.03M | 20.89M | 970.00K | 1.22M | 1.29M | 1.37M | 3.46M | 3.32M | 7.18M | 10.97M | 30.02M | - | 27.77M | 22.26M | 76.32M | 108.25M | 25.56M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.31M | 48.43M | 41.62M | 41.35M | 60.19M |
| Operating Income | -1.14M | 2.36M | -1.07M | -3.17M | -9.99M | -2.56M | -9.09M | -7.15M | -15.76M | -14.41M | -16.89M | -19.66M | -24.77M | -26.66M | -33.74M | -22.26M | -10.25M | -22.64M | -24.34M | -18.36M | -533.00K | -6.76M | -31.75M | -27.80M | -29.63M | -44.40M | -40.14M | -37.73M | -42.20M | -40.32M | -22.76M | - | -27.54M | -26.17M | 34.70M | 66.90M | -34.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.62M | -18.38M | 38.24M | 70.01M | -31.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.06M | 19.61M | 22.52M | 19.71M | 20.86M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.28M | -38.59M | 15.11M | 49.70M | -52.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.00K | 39.00K | 0 | 81.00K | 40.00K |
| Net Income | -888.00K | 2.32M | -1.11M | - | -11.44M | -2.68M | -9.09M | - | -15.09M | -13.62M | -15.96M | - | -22.08M | -23.96M | -31.03M | - | -8.26M | -21.55M | -23.77M | -18.16M | -429.00K | -6.67M | -36.26M | -32.55M | -33.50M | -44.26M | -39.84M | -37.31M | -43.94M | -46.66M | -32.85M | - | -39.33M | -38.63M | 15.11M | 49.61M | -52.88M |
| Diluted EPS | -0.34 | 0.05 | -0.42 | -1.73 | -0.75 | -0.13 | -0.45 | -0.30 | -0.63 | -0.57 | -0.66 | -0.64 | -0.82 | -0.89 | -1.15 | -0.75 | - | -0.79 | -0.87 | -0.66 | -0.02 | -0.24 | -1.31 | -1.15 | -1.18 | -1.58 | -1.50 | -1.41 | -1.64 | -1.71 | -1.14 | - | -1.28 | -1.34 | 0.52 | 1.58 | -1.84 |
| R&D Expense | 4.79M | 2.33M | 3.28M | - | 7.93M | 7.21M | 6.70M | - | 11.81M | 10.58M | 17.88M | - | 20.63M | 27.35M | 29.93M | - | 20.97M | 17.95M | 19.54M | 24.18M | 25.31M | 22.22M | 22.52M | 20.84M | 22.06M | 34.96M | 32.92M | 30.88M | 37.04M | 42.00M | 42.21M | - | 41.18M | 37.82M | 31.41M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.57M | 16.68M | 10.00M | 5.00M | 8.00M | 75.00M | 63.17M | 10.29M | 17.16M | 91.28M | 234.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 125.44M | 174.23M | 206.23M | 186.71M |
| Operating Income | -3.32M | -3.02M | -28.78M | -66.72M | -107.43M | -23.88M | -56.81M | -115.15M | -157.07M | -114.95M | 47.90M |
| EBITDA | - | - | - | - | - | - | - | -105.26M | -143.16M | -92.74M | 69.25M |
| Interest Expense | - | - | - | - | - | - | - | 21.11M | 18.08M | 50.09M | 79.89M |
| Pretax Income | - | - | - | - | - | - | - | -128.70M | -163.62M | -145.23M | -13.07M |
| Tax Provision | - | - | - | - | - | - | - | 24.00K | -4.00K | 3.00K | 164.00K |
| Net Income | -5.41M | -4.26M | -30.07M | -61.66M | -97.34M | -19.93M | -57.80M | -128.72M | -163.62M | -145.23M | -13.23M |
| Diluted EPS | - | -1.62 | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.46 |
| R&D Expense | 17.30M | 15.42M | 29.44M | 56.20M | 99.34M | 80.03M | 98.50M | 88.80M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.18M | 329.36M | 509.00M | 435.20M | 416.55M | - | 610.38M | 452.39M | 483.83M | 364.39M |
| Current Assets | - | - | - | - | - | - | - | - | 447.20M | 406.83M | 431.88M | 350.25M |
| Cash & Equivalents | - | - | 51.23M | 81.19M | 113.60M | 171.02M | 250.46M | - | 71.31M | 35.97M | 123.08M | 238.20M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 1.42M | 6.85M | 40.77M | 33.85M |
| Total Liabilities | - | - | - | - | - | - | - | - | 348.28M | 364.29M | 412.97M | 327.19M |
| Current Liabilities | - | - | 5.71M | 14.09M | 21.84M | 29.54M | 19.82M | - | 26.05M | 37.44M | 45.43M | 38.62M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 19.45M | 17.81M | 16.04M | 14.11M |
| Total Equity | -30.84M | -35.18M | -38.25M | 307.58M | 486.37M | 405.01M | 396.73M | - | 262.10M | 88.10M | 70.87M | 37.21M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 28.51M | 26.60M | 30.47M | 28.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.69M | -9.03M | -19.44M | -48.51M | -69.52M | -14.16M | - | -73.59M | -120.80M | -135.34M | 19.70M |
| Investing Cash Flow | -238.00K | -50.00K | -243.06M | -142.45M | 131.43M | 94.47M | - | -394.85M | 144.75M | 95.40M | 228.03M |
| Financing Cash Flow | 39.40M | 8.63M | 292.45M | 223.36M | -4.49M | -879.00K | - | 44.02M | -59.30M | 127.05M | -132.61M |
| Capital Expenditure | -238.00K | -50.00K | -290.00K | -1.06M | -805.00K | -569.00K | - | -358.00K | -807.00K | -358.00K | -87.00K |
| Free Cash Flow | -9.93M | -9.08M | -19.73M | -49.57M | -70.32M | -14.73M | - | -73.95M | -121.61M | -135.69M | 19.61M |
| Net Change in Cash | - | - | - | - | - | - | - | -424.42M | -35.34M | 87.11M | 115.12M |
| Share Buybacks | 0 | 1.00K | 0 | 0 | - | - | 0 | 0 | 50.00M | 456.00K | 68.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -18.9% | -18.1% | -287.8% | -1,334.4% | -1,342.9% | -31.8% | -89.9% | -1,119.4% | -915.5% | -125.9% | 20.4% |
| Net Margin % | -30.8% | -25.5% | -300.7% | -1,233.1% | -1,216.7% | -26.6% | -91.5% | -1,251.3% | -953.7% | -159.1% | -5.6% |
| ROE % | 15.4% | 11.1% | -9.8% | -12.7% | -24.0% | -5.0% | - | -49.1% | -185.7% | -204.9% | -35.6% |
| ROCE % | - | -5.4% | -9.1% | -13.7% | -26.5% | -6.0% | - | -19.7% | -37.9% | -26.2% | 14.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 26.61% | 7.88M | $443.49M |
| 2 | Blackrock Inc. | 6.23% | 1.84M | $103.78M |
| 3 | Tang Capital Management, LLC | 4.49% | 1.33M | $74.90M |
| 4 | State Street Corporation | 4.34% | 1.29M | $72.39M |
| 5 | Vanguard Capital Management LLC | 3.06% | 906.23K | $51.00M |
| 6 | Affinity Asset Advisors, Llc | 2.79% | 826.11K | $46.49M |
| 7 | Sanofi | 2.78% | 821.92K | $46.26M |
| 8 | Millennium Management Llc | 2.73% | 807.32K | $45.44M |
| 9 | Woodline Partners LP | 2.42% | 717.01K | $40.35M |
| 10 | 683 Capital Management LLC | 2.23% | 660.00K | $37.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANAB
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial o…
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating prog…
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in…
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock w…
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal fo…
ANAB — Frequently Asked Questions
What is the current share price of AnaptysBio, Inc. (ANAB)?
As of 2026-09-07 16:24 PDT, AnaptysBio, Inc. (ANAB) trades at $56.80 on NasdaqGS. Its 52-week range is $12.93 to $69.81.
What is the market capitalisation of ANAB?
AnaptysBio, Inc. (ANAB) has a market capitalisation of $1.68B on NasdaqGS.
What is the P/E ratio of ANAB?
ANAB trades at a trailing price-to-earnings (P/E) ratio of -55.69. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 128.95.
What is the return on equity (ROE) of ANAB?
ANAB has a return on equity (ROE) of -114.55%. Its return on capital employed (ROCE) is 14.70%.
Is ANAB a good stock to buy?
This page provides a data-driven analysis of AnaptysBio, Inc. (ANAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.